BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33742122)

  • 1. Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation.
    Wang YH; Chan YT; Hung TH; Hung JT; Kuo MW; Wang SH; Huang Y; Lin YJ; Chen SC; Yu JC; Wu JC; Yu J; Yu AL
    Oncogene; 2021 Apr; 40(16):2858-2871. PubMed ID: 33742122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation.
    Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL
    Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.
    Bahena-Ocampo I; Espinosa M; Ceballos-Cancino G; Lizarraga F; Campos-Arroyo D; Schwarz A; Maldonado V; Melendez-Zajgla J; Garcia‐Lopez P
    EMBO Rep; 2016 May; 17(5):648-58. PubMed ID: 27113763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
    Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
    Front Immunol; 2021; 12():791551. PubMed ID: 35046949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
    Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
    J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
    Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
    Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Liao YM; Wang YH; Hung JT; Lin YJ; Huang YL; Liao GS; Hsu YL; Wu JC; Yu AL
    Breast Cancer Res; 2021 Jan; 23(1):5. PubMed ID: 33413566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147
    Lv Y; Wang T; Fan J; Zhang Z; Zhang J; Xu C; Li Y; Zhao G; He C; Meng H; Yang H; Wang Z; Liu J; Chen J; Wang L
    Tumour Biol; 2017 Apr; 39(4):1010428317695927. PubMed ID: 28381172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation.
    Li B; Lu Y; Yu L; Han X; Wang H; Mao J; Shen J; Wang B; Tang J; Li C; Song B
    Chem Biol Interact; 2017 Nov; 277():33-42. PubMed ID: 28844858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and characterization of transmembrane and coiled-coil domain family 3.
    Sohn WJ; Kim JY; Kim D; Park JA; Lee Y; Kwon HJ
    BMB Rep; 2016 Nov; 49(11):629-634. PubMed ID: 27697108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
    Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels.
    Wen S; Qin Y; Wang R; Yang L; Zeng H; Zhu P; Li Q; Qiu Y; Chen S; Liu Y; Hou Y; Tang X; Liu M; Tu G
    Cell Death Dis; 2021 May; 12(5):437. PubMed ID: 33934099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.
    Smit L; Berns K; Spence K; Ryder WD; Zeps N; Madiredjo M; Beijersbergen R; Bernards R; Clarke RB
    Oncotarget; 2016 Jan; 7(3):2596-610. PubMed ID: 26595803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.